Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Completed · Phase 3 · Has a placebo group

Conditions studied: Pain, Advanced Cancer

In brief

This 9-week study aimed to determine the efficacy, safety and tolerability of nabiximols (Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in participants with advanced cancer. Eligible participants were not required to stop any of their current treatments or medications.

Key facts

Study ID
NCT01262651
Run by
GW Pharmaceuticals Ltd
People needed
397
Starts
2010-11-25
Expected to finish
2015-07-02
Last updated by the study team
2018-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.